Velgia® is a drug containing the active ingredient semaglutide, which is prescribed as an adjunct to a low–calorie diet and physical activity to correct and control body weight. Semaglutide belongs to the treatment of diabetes mellitus; hypoglycemic agents, except insulins. Semaglutide is an analog of the natural hormone glucagon–like peptide-1 (GLP-1), which is released after eating and serves as a physiological regulator of carbohydrate metabolism (insulin and glucose levels), as well as appetite and food intake. Semaglutide acts on targets (receptors) in the brain that control appetite, which helps you feel full faster, maintain this feeling for a long time and reduce increased cravings for food.

Velgia® is used in adults over 18 years of age as an adjunct to a low-calorie diet and physical activity to control body weight, including weight loss and maintenance, with an initial body mass index (BMI):

• ≥ 30 kg/m² (obese) or
• ≥ 27 kg/m² up to <30 kg/m² (overweight) in the presence of at least one overweight-related concomitant disease, such as prediabetes or type 2 diabetes mellitus (DM2), high blood pressure (hypertension), deviation from the normal level of blood lipids (fats) (dyslipidemia), respiratory disorders during sleep (obstructive sleep apnea syndrome) or cardiovascular diseases.

Seek immediate medical attention if you have injected Velgia® more than you should have. You may experience undesirable reactions such as nausea, vomiting, or diarrhea (diarrhea), which can cause dehydration (loss of body fluids).

Stop taking the drug and seek medical help immediately if one of the following signs of a severe allergic reaction (anaphylactic reactions, angioedema) occur, which may occur rarely (in no more than 1 person out of 1000):

• difficulty breathing or swallowing
• vertigo
• fainting condition (drop in blood pressure) with rapid heartbeat and increased sweating
• swelling of the face, lips, tongue or throat
• severe itching of the skin, the appearance of rashes or blisters

If you have diabetes, you should inform your doctor if you experience severe visual impairment during treatment with Velgia®, this may be a sign of an exacerbation of diabetic retinopathy, which may occur frequently (no more than 1 in 10 people) .

Stop taking the drug and seek medical help immediately if one or more of the following symptoms of pancreatic inflammation (acute pancreatitis) occur, which may occur infrequently (no more than 1 in 100 people ):

• severe and prolonged abdominal pain that may radiate to the back
• pain all over my stomach
• deterioration of condition (marked weakness, sweating, rapid heartbeat)
• increased body temperature

Do not use Velgia®:

• If you are allergic to semaglutide or any other components of the drug (listed in section 6 of the leaflet)
• If you have a history of medullary thyroid cancer, including family history
• If you have multiple endocrine neoplasia (MEN) type 2, a group of hereditary endocrine diseases that cause benign and malignant neoplasms
• If you have type 1 diabetes mellitus (DM1)
• If you have diabetic ketoacidosis (an acute complication of diabetes mellitus associated with impaired carbohydrate metabolism due to insulin deficiency)
• If you are under 18 years old

Tell your doctor that you are taking, have recently taken, or may start taking any other medications.
Semaglutide affects the absorption of other drugs in the gastrointestinal tract. It is important to take this into account for drugs that require rapid absorption into the gastrointestinal tract.
This may be especially important if you are taking any of the following medications:
Warfarin or similar drugs taken orally to reduce blood clotting (oral anticoagulants). When you start treatment, for example, with warfarin or similar drugs, you may need to have a frequent blood test to determine blood clotting parameters. 

Registration certificate holder Russian Federation PROMOMED RUS LLC Address: 13 Mira Avenue, building 1, office 13, Moscow, 129090, Phone: +7 (495) 640-25-28
Manufacturer (1)
Russian Federation JSC Biochemist Address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia
Manufacturer (2)
Russian Federation OOO "Plant Medsintez" Address: 624130, Sverdlovsk region, Novouralsk, Trade street, 15, building 3
Organization that accepts consumer claims
PROMOMED RUS LLC, Russia.
13 Mira Ave., building 1, Moscow, 129090.
Tel.: 8-800-777-86-04 (free of charge), 8-495-640-25-28.
E-mail: reception@promo-med.ru

Store at a temperature of 2 to 8 degrees Celsius (in the refrigerator), but not near the freezer. Protect from light. Do not freeze. A syringe pen with the drug that is used or carried as a spare should be stored at a temperature of no more than 30 ° C or at a temperature of 2 to 8 ° C (in the refrigerator) for 6 weeks. Do not freeze. After use, cover the pen with a cap to protect it from light.

Velgia® has no or negligible effect on the ability to drive vehicles or operate machinery. However, some patients may experience dizziness during semaglutide treatment, mainly during the first 4 months of treatment (during the dose increase period). If you feel dizzy, be especially careful when driving or working with machinery. If you need more information, please contact your doctor.